211 related articles for article (PubMed ID: 30132131)
21. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
[TBL] [Abstract][Full Text] [Related]
22. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
23. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
24. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
25. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
26. Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.
Lopez C; Schleussner N; Bernhart SH; Kleinheinz K; Sungalee S; Sczakiel HL; Kretzmer H; Toprak UH; Glaser S; Wagener R; Ammerpohl O; Bens S; Giefing M; Sanchez JCG; Apic G; Hubschmann D; Janz M; Kreuz M; Mottok A; Muller JM; Seufert J; Hoffmann S; Korbel JO; Russell RB; Schule R; Trumper L; Klapper W; Radlwimmer B; Lichter P; Kuppers R; Schlesner M; Mathas S; Siebert R
Haematologica; 2023 Feb; 108(2):543-554. PubMed ID: 35522148
[TBL] [Abstract][Full Text] [Related]
27. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ
Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
[TBL] [Abstract][Full Text] [Related]
29. [Immune-checkpoint and hemopathies].
Burroni B; Broudin C; Damotte D; Laurent C
Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
[TBL] [Abstract][Full Text] [Related]
30. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
Peeters P; Raynaud SD; Cools J; Wlodarska I; Grosgeorge J; Philip P; Monpoux F; Van Rompaey L; Baens M; Van den Berghe H; Marynen P
Blood; 1997 Oct; 90(7):2535-40. PubMed ID: 9326218
[TBL] [Abstract][Full Text] [Related]
31. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
[TBL] [Abstract][Full Text] [Related]
32.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
33. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
[TBL] [Abstract][Full Text] [Related]
34. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
Mark HF; Sotomayor EA; Nelson M; Chaves F; Sanger WG; Kaleem Z; Caughron SK
Exp Mol Pathol; 2006 Dec; 81(3):217-23. PubMed ID: 16959246
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
36. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
[TBL] [Abstract][Full Text] [Related]
37. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
38. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
39. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]